{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:39:16Z","timestamp":1790757556643,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ando.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T16:12:29Z","timestamp":1617898349000},"page":"74-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["1921\u20132021: From insulin discovery to islet transplantation in type\u00a01 diabetes"],"prefix":"10.1016","volume":"82","author":[{"given":"Mikael","family":"Chetboun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kerr-Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pattou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2021.03.006_bib0115","first-page":"dc202458","article-title":"Survival After Islet Transplantation in Subjects With Type 1 Diabetes: Twenty-Year Follow-Up","author":"Lemos","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0120","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(19)31334-0","article-title":"Advances in \u03b2-cell replacement therapy for the treatment of type 1 diabetes","volume":"394","author":"Vantyghem","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2021.03.006_bib0125","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2337\/dc15-0090","article-title":"Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia","volume":"38","author":"Choudhary","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2018.07.006","volume":"45","author":"Wojtusciszyn","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2021.03.006_bib0135","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2021.02.339","article-title":"Transplant Options for Patients with Diabetes and Advanced Kidney Disease","author":"Kukla","year":"2021","journal-title":"Am J Kidney Disease"},{"key":"10.1016\/j.ando.2021.03.006_bib0140","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2589-7500(19)30003-2","article-title":"Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial","volume":"1","author":"Benhamou","year":"2019","journal-title":"Lancet Digital Health"},{"key":"10.1016\/j.ando.2021.03.006_bib0145","first-page":"dc202250","article-title":"Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes","author":"Collyns","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0150","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.2337\/dc20-1447","article-title":"Australian JDRF Closed-Loop Research Group. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial","volume":"43","author":"McAuley","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0155","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0160","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc19-0401","article-title":"Ten-year outcome of islet alone or after kidney transplantation in type 1 diabetes: A prospective parallel arm cohort study","volume":"42","author":"Vantyghem","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0165","doi-asserted-by":"crossref","first-page":"E2078","DOI":"10.1210\/jc.2012-2115","volume":"97","author":"Vantyghem","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.03.006_bib0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2337\/dc14-1656","article-title":"Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation","volume":"38","author":"Brooks","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0175","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2337\/db13-0881","article-title":"DCCT\/EDIC Research Group Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial","volume":"63","author":"Lachin","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2021.03.006_bib0180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00125-020-05099-3","article-title":"J Strachan Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes","volume":"63","author":"Gibb","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2021.03.006_bib0185","doi-asserted-by":"crossref","first-page":"e143011","DOI":"10.1172\/JCI143011","article-title":"DCCT\/EDIC Research Group Residual \u03b2 cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia","volume":"131","author":"Gubitosi-Klug","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2021.03.006_bib0190","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/dme.13960","article-title":"TIGI consortium. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA(1c) in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?","volume":"36","author":"Marren","year":"2019","journal-title":"Diabet Med"},{"key":"10.1016\/j.ando.2021.03.006_bib0195","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/dc20-0567","article-title":"Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications","volume":"44","author":"Jeyam","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2021.03.006_bib0205","article-title":"Glucagon blockade restores functional \u03b2-cell mass in type 1 diabetic mice and enhances function of human islets","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ando.2021.03.006_bib0210","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2337\/dc19-2288","article-title":"C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet","volume":"43","author":"Bogun","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2021.03.006_bib0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S2213-8587(17)30001-3","article-title":"Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study","volume":"5","author":"Bally","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2021.03.006_bib0220","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(18)31947-0","article-title":"APCam11 Consortium. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial","volume":"392","author":"Tauschmann","year":"2018","journal-title":"Lancet"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T23:38:18Z","timestamp":1671665898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426621000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0003426621000317"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2021.03.006","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1921\u20132021: From insulin discovery to islet transplantation in type\u00a01 diabetes","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}